GlassScriptPhysician profile
Harry Antonius Lee
NPI 1225029259
$10,497.44
in general payments reported to CMS, 2019-2025
31 companies · $1,861 in 2025
The $1,861 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,269 · 2020: $875 · 2021: $1,408 · 2022: $1,362 · 2023: $1,622 · 2024: $2,100 · 2025: $1,861.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,294 · Education: $259 · Consulting Fee: $30.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,293.64 |
| Education | $258.90 |
| Consulting Fee | $30.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,672.89 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Glaxosmithkline, LLC. | $1,747.55 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Genentech USA, INC. | $1,122.97 | 2019-2025 | Xolair |
| Csl Behring | $1,101.38 | 2020-2025 | Haegarda, Kcentra, Andembry |
| Regeneron Healthcare Solutions, INC. | $759.76 | 2019-2025 | Dupixent |
| Genzyme Corporation | $477.65 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $417.03 | 2019-2025 | |
| Octapharma USA, INC. | $290.81 | 2022-2025 | Panzyga, Cutaquig |
| Amgen INC. | $269.47 | 2021-2025 | Tezspire |
| Teva Pharmaceuticals USA, INC. | $242.53 | 2019-2023 | Cinqair |
| Pfizer INC. | $230.65 | 2019-2025 | |
| Pharming Healthcare, INC. | $146.99 | 2022-2025 | Ruconest |
| Alk-Abello, INC | $121.64 | 2021-2022 | |
| Aimmune Therapeutics, INC. | $104.98 | 2020-2022 | |
| Adma Biomanufacturing LLC | $99.98 | 2021-2024 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $84.29 | 2020-2022 | |
| Optinose US, INC. | $69.28 | 2019-2020 | |
| Grifols USA, LLC | $66.59 | 2023-2024 | Xembify |
| Takeda Pharmaceuticals U.S.A., INC. | $66.00 | 2021-2023 | Takhzyro |
| Sanofi-Aventis U.S. LLC | $54.95 | 2024 | |
| Biocryst US Sales Co., LLC | $51.02 | 2021-2024 | Orladeyo |
| Genentech, INC. | $49.95 | 2024 | Xolair |
| Dermavant Sciences, INC. | $44.31 | 2024 | Vtama |
| Merck Sharp & Dohme LLC | $41.39 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.09 | 2019-2020 | |
| Ars Pharmaceuticals Operations, INC. | $24.06 | 2025 | Neffy |
| Horizon Therapeutics Plc | $23.44 | 2021 | |
| Jubilant Hollisterstier LLC | $23.22 | 2021 | |
| Medtronic USA, INC. | $22.53 | 2020 | |
| Galderma Laboratories, L.P. | $18.26 | 2025 | Nemluvio |
| Organon LLC | $10.78 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harry Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.